Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

rthritis. ChemoCentryx is privately held. For more information, please refer to http://www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's business model, strategic plans for its business, product candidates and technology, (vi) ChemoCentryx's ability to maintain and establish collaborations or obtain additional government grant funding, (vii) ChemoCentryx's estimates of its expenses, future revenues, capital requirements and its needs for additional financing, (viii) the timing or likelihood of regulatory filings and approvals, (ix) the availability of corporate partners, (x)
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN MARCOS, Texas , Nov. 21, 2014 /PRNewswire/ ... industrial hemp containing low THC, announces they are now ... is comparable to Charlotte,s Web type strains grown in ... symptoms from other neurological disorders, such as Parkinson,s, MS, ... waiting for US laws to pass, because imported CBD ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... Inc. (NYSE: LDR) announced today that its Board of ... share for the second quarter of fiscal 2012. The dividend will ... on March 9, 2012. About Landauer ... services to determine occupational and environmental radiation exposure and is ...
... BRUSSELS, Feb. 28, 2012 Eli Lilly and Company (NYSE: ... global Innovation Starts Here initiative which supports Lilly,s commitment to ... the world. Two key components of this ... Innovation Fellowship Awards. Through both, Lilly scientists will collaborate with ...
Cached Medicine Technology:Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 2Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 3Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 4Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 5
(Date:11/21/2014)... Orange County, CA (PRWEB) November 21, 2014 ... be featured in an upcoming episode of Innovations with ... 2015. Dates and show times TBA. , Big Bud ... with information for growing, harvesting, and utilization of medical ... look at Big Bud Farms’ wide variety of products ...
(Date:11/21/2014)... November 21, 2014 Launched today on ... is an all-in-one senior care coordination tool designed to ... ones simple and intuitive for family members and caregivers ... centers). Now, the family caregiver or home health aide ... activities, health data, medical records, goals, schedules, and even ...
(Date:11/21/2014)... November 21, 2014 TruDenta, the creator ... headaches and other jaw-related symptoms, has reported a ... from chronic head pain, neck pain, TMJ (temporomandibular joint) ... year we have seen a 52% increase in the ... of over 300 doctors and their teams in 47 ...
(Date:11/21/2014)... 2014 CDT PLUS! 2015 ... It includes everything needed to process dental insurance claims. ... CDT , CDT 2015 codes are mandatory for reporting ... - December 31, 2014. Dental professionals must use HIPAA ... dental claims. There are significant changes in the CDT ...
(Date:11/21/2014)... November 21, 2014 TopConsumerReviews.com recently ... an industry leader in the relief of ... significant feelings of sadness and depression each year ... pharmaceutical choices. Often, prescription drugs can produce worse ... drugs are expensive and require regular follow-up visits ...
Breaking Medicine News(10 mins):Health News:Big Bud Farms to be Featured in Upcoming Episode of Innovations with Ed Begley Jr. 2Health News:Comprehensive Senior Care Application Launched on Apple App Store 2Health News:National Rise In Patients Seeking Headache Relief 2Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2
... New Delhi: The National AIDS Control Organization (NACO) has ... to provide free anti-retroviral treatment (ART). //The count of ... on the anvil. , ,These centers will support ... the services of exclusive doctors, counselors and laboratory technicians ...
... or get the consent of one or both parents before ... to a Florida State University law professor in Tallahassee, Fla. ... and Thomas Stratmann, professor of economics at George Mason University, ... of gonorrhea among teenage girls as a measure of risky ...
... reduce their risk of becoming obese children, even if ... a study led by a researcher at the University ... ,The findings contradict an earlier, smaller study that found ... diabetes had poor glucose tolerance, a precursor to diabetes, ...
... self-image as the “strong, silent type” and the stigma ... less likely than women to be referred to studies ... recognize and express symptoms of depression, according to clinicians ... UC Davis Department of Psychiatry and Behavioral Sciences. ...
... tennis elbow and a wait and watch approach may be ... Australian researchers tested this approach in one group of volunteers, ... ,A second group were given a local ... The final group received eight treatments of physiotherapy of 30 ...
... amphetamine abuse in the Asia-Pacific region has hit high levels ... problem threatening Asia that is this big is a problem ... Australia as is the security of Australia in terms of ... the United Nations Office of Drugs and Crime told AFP. ...
Cached Medicine News:Health News:Abortion Notification, Consent Laws Reduce Risky Teen Sex 2Health News:Breast-Feeding May Reduce Childhood Obesity 2Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 2Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 3Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 4Health News:Steroids Ineffective In Tennis Elbow 2
... Medical Records module is designed to ... and increase revenues. It creates and ... effort while it streamlines workflow, controls ... to patient care outcomes. NextGen EMR ...
... of products offers complete electronic medical ... Intuition EMR enables physicians to create ... at the point of care, and ... on documentation and more time on ...
... Misys Healthcare Systems provides specialty-specific EMR ... Because we've worked with physician practices for ... doesn't fit the needs of every organization. ... components. Modules such as orders management ...
... of our leading products. Perhaps it's ... what Compulink first developed over 15 ... leaders in the ophthalmic practice management ... the functionality of a busy Optometric ...
Medicine Products: